Webinar Video Library

PNH: New Therapeutic Update
Jeff Szer
November 30, 2023

Is it possible to Provide the Art of Personalized Cell Therapy in the Era of Increasing Computer Driven Care?
Finn Bo Petersen
October 26, 2023

HTLV-related malignancies: Where do we stand?
Shigeo Fuji
September 28, 2023

Clonal Hematopoiesis: Origins and Clinical Implications
Lourdes Mendez
August 1, 2023

Treatment of Acute Lymphoblastic Leukemia, with a Special Focus on the Role of Asparaginase and Conventional Chemotherapy
André Baruchel, Nicolas Boissel, Jose-Maria Ribera, Kjeld Schmiegelow, Inge Van Der Sluis, Mohamad Mohty
July 4, 2023

A Focus on Small Molecules in Myeloma
Lisa Leypoldt, Elias Mai, Maximilian Merz, Mohamad Mohty
July 3, 2023

Management of Refractory Anemia in Myeloid Malignancies
Matteo Della Porta
June 26, 2023

Management of Waldenstrom Macroglobulinemia: an update
Monique Minnema
May 24, 2023

Optimising transplant outcome in adults allografted for AML
Charles Craddock
May 3, 2023

Allogeneic stem cell transplantation for older patients: where do we stand?
Didier Blaise
April 18, 2023

Non alcoholic fatty liver disease: a global health challenge not sparing hematology
Pierre Brissot
March 29, 2023

Management of chronic myeloid leukemia: an update
De Lavallade Hugues
March 15, 2023

Post-TCT Review: Transplant and Cellular Therapy (Part 2)
Dr. Bipin Savani
March 28, 2023

Post-TCT Review: Transplant and Cellular Therapy (part 1)
Bipin Savani
March 14, 2023

Telemedicine in hematology: where do we stand?
Malte Jacobsen, Alberto Mussetti, Jonas Paludo
March 7, 2023

Current and Future Haemophilia Treatments
Michael Makris
Feb. 28, 2023

Bi-and tri-specific antibodies in non-Hodgkin Lymphoma: current data and perspectives
Clémentine Sarkozy
January 19, 2023

Bench at Bedside Models Facilitate CAR-T Cell Supply Chain
Folashade Otegbeye
January 3, 2023

Gene therapy in hemoglobinopathies
Haydar Frangoul
December 20, 2022

ITP: novel treatments
James B Bussel
December 5, 2022

Bispecific antibodies in lymphoma: an update
Mazyar Shadman
November 29, 2022

Diagnostic and therapy of Ph-like acute lymphoblastic leukemia
Ibrahim Aldoss
November 7, 2022

Management of T-ALL: an update
Huang Xiao Jun
November 2, 2022

IDH inhibitors in relapsed/refractory AML
Pau Montesinos Fernandez
October 19, 2022

Machine learning and artificial intelligence in Hematology
Roni Shouval
October 3, 2022

Management of patients with Fanconi Anemia
Carmem Bonfim
June 30, 2022

CAR-T Cells in Lymphoma: the latest data
Roch Houot
May 19, 2022

GVHD in 2022: from prevention to therapy
Bipin Savani
April 12, 2022

Updates in Chronic Graft-versus-Host Disease (GVHD) Management
Catherine J. Lee
Mar. 24, 2022

Immune-based approaches in AML
Naval Daver
Dec. 8, 2021

Targeted Therapies in AML
Naval Daver
Dec. 7, 2021

Alkylating agents: old dogs with new tricks
Didier Blaise, Remy Dulery, Arnon Nagler, Mohamad Mohty
Nov. 15, 2021

Systemic Mastocytosis
Celalettin Ustun
Nov. 4, 2021

Management of CLL in 2021 and Beyond
Nitin Jain
Oct. 19, 2021

Novel Therapeutic Approaches in BPDCN : Targeting CD123 and Beyond
Naveen Pemmaraju
Sept. 30, 2021

HTLV-1 associated malignancies: from diagnosis to treatment
Ali Bazarbachi
Sept. 16, 2021

 
Dr. Rémy Duléry
July 22, 2021

 
Prof. Amer Zeidan

 
Prof. Bipin Savani
May 26, 2021

 
Dr. Remy Dulery

Hemochromatosis: what’s important and new in 2020?
Prof. Pierre Brissot

Post-Transplant Complications: A Focus on Veno-Occlusive Disease (VOD)
Prof. Mohamad Mohty

TPO agents beyond ITP: aplastic anemia, inherited thrombocytopenia and chemotherapy induced thrombocytopenia
Prof. James Bussel

Current perspectives on management of AL amyloidosis
Eli Muchtar, M.D

Cold Agglutinin Disease Laboratory Evaluation and Treatment Options
Garrett S. Booth, M.D.

Therapeutic options for sickle cell disease in 2019
Prof. Selim Corbacioglu

Management of relapsed DLBCL in era of CAR-T therapy
Dr. Veronika Bachanova

What should you know on what is new in aplastic anemia
Prof. Phillip Scheinberg

MPN – Whom to transplant, when and how
Prof. H. Joachim Deeg

Indications for allogeneic stem cell transplantation in AML
Arnon Nagler, M.D., M.Sc

Measurable Residual Disease in Acute Myeloid Leukemia (MRD in AML)
Prof. Christopher S. Hourigan DM DPhil FACP FRCP

Host-microbiome symbiosis in health and disease
Dr. Joël Doré

Nutritional supplements and complementary/alternative medical practices in patients with hematologic diseases
Prof. Bipin N. Savani

CD19 CAR T cells in lymphoid malignancies – 2018 Update
Miguel-Angel Perales, MD

Therapy of relapsed multiple myeloma – An update
Mohamad Mohty, MD, PhD

IACH Webinars dedicated to the COVID-19 pandemic

The COVID-19 pandemic emergency and young physicians: life before and after the crisis?
Carolina Marini, Mohamad Mohty

The COVID-19 pandemic emergency and hematology: reporting live from the ICU
Giovanni Landoni, Mohamad Mohty

The COVID-19 pandemic emergency and management of acute leukemia: challenges and options
Naveen Pemmaraju, Mohamad Mohty

The COVID 19 pandemic emergency and hematology a psychologist perspective
Yolande Arnault, Mohamad Mohty

The COVID-19 pandemic emergency and the ethics of research
Philippe Gabriel Steg, Mohamad Mohty

A COVID-19 personal experience: when a hematologist becomes a patient as well as caregiver 
Noopur Raje, Mohamad Mohty

The COVID-19 pandemic emergency and hematology: experience and perspectives from Italy 
Mohamad Mohty, Annalisa Ruggeri

Management of multiple myeloma during COVID 19
Prof. Mohty, Prof. Mateos

COVID-19 and hematological malignancies: a few practical issues
Prof. Mohty, Prof. Chabannon

CAR-T cells in lymphoid diseases: A web-conference by the IACH (April 4, 2020)

Results in adult ALL
Prof. Jordan Gauthier

Results in lymphoma  
Prof. Saad Kenderian

Results in myeloma  
Prof. Mohamad Mohty

The IACH 2021 webinars are supported in part by an unrestricted educational grant provided by Amgen